MedTrace Logo

The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism

NCT01768429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2014-12-03

No results posted yet for this study

Summary

The aim of the project is to examine whether the sources of n-3 fatty acids and fish itself differ in their effects on glucose metabolism, lipid metabolism, blood pressure, and serum inflammatory markers. Lipidomic profiles and gene expression will be used for thorough assessment of the possible clinical changes. The study will compare the effects of alpha-linolenic acid containing vegetable oil, fatty fish, lean fish and control diet. The results of this project will help to identify the optimal source of n-3 fatty acids, and reveal the significance of the components of fish other than fatty acids. These data will be useful both nationally and internationally, since highly controlled dietary interventions utilizing new methodology are scarce.

Conditions

Interventions

BEHAVIORAL

Fatty fish

BEHAVIORAL

Lean Fish

BEHAVIORAL

Alpha-linolenic acid

BEHAVIORAL

Control

Sponsors & Collaborators

  • Kuopio University Hospital

    collaborator OTHER

  • VTT Technical Research Centre, Finland

    collaborator OTHER

  • University of Eastern Finland

    lead OTHER

Principal Investigators

  • Arja Erkkilä, Adjunct Prof · University of Eastern Finland

  • Ursula Schwab, Adjunct Prof · University of Eastern Finland

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-06-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768429 on ClinicalTrials.gov